Retrospective cohort study for evaluating the INR monitoring patterns in patients with deep vein thrombosis in daily practice: Analysis of 2010–2013 database of a tertiary care center
Restricted accessResearch articleFirst published online June, 2019
Retrospective cohort study for evaluating the INR monitoring patterns in patients with deep vein thrombosis in daily practice: Analysis of 2010–2013 database of a tertiary care center
To evaluate the international normalized ratio (INR) monitoring patterns in patients with deep vein thrombosis.
Methods
Of 32,012 patients with ≥1 outpatient INR measurement and 42,582 patients with confirmed deep vein thrombosis diagnosis registered to our hospital between 1 January 2010 and 31 December 2013, 6720 records were identified to have both deep vein thrombosis and international normalized ratio measurement, and 4.377 out of 6.720 single patient records were determined to be statistically analyzable.
Results
Median INR measurement frequency was 6.47 times/year and patients had INR levels of 2–3 in 34.3% of follow-up time. Having ≥70% vs. <70% of follow-up time within therapeutic range was associated with lower hospital admission frequency (9.7 vs. 10.3 times/year).
Conclusion
Our study revealed only one-third of the follow-up time to be spent within therapeutic INR, association of INR therapeutic range with lesser number of hospital admissions and INR monitoring frequency of 6.47 times/year despite lack of stable INR control in most of the deep vein thrombosis patients.
AgenoWGallusASWittkowskyAet al.
Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;
141: e44S–88S.
2.
JacksonMCEsnoufPMLindahlT.A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy.Pathophysiol Haemost Thromb2003;
33: 43–51.
3.
GemmatiDBuriniFTalaricoAet al.
The active metabolite of warfarin (3'-hydroxywarfarin) and correlation with INR, warfarin and drug weekly dosage in patients under oral anticoagulant therapy: a pharmacogenetics study.PLoS One2016;
11: e0162084.
4.
HolbrookASchulmanSWittDMet al.
Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;
141: e152S–e184S.
5.
AmiweroCCampbellIAPrescottRJ.A re-appraisal of warfarin control in the treatment of deep vein thrombosis and/or pulmonary embolism.Afr Health Sci2009;
9: 179–185.
6.
AnsellJHirshJHylekEet al.
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence based clinical practice guidelines, 8th ed. Chest2008;
133: 160–198.
7.
ShapiroNISpearJSheehySet al.
Barriers to the use of outpatient enoxaparin therapy in patients with deep venous thrombosis.Am J Emerg Med2005;
23: 30–34.
8.
PhillipsKWAnsellJ.Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.Expert Rev Cardiovasc Ther2008;
6: 57–70.
9.
ErkensPMten CateHBüllerHRet al.
Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.PLoS One2012;
7: e42269.
10.
FitzmauriceDA.Oral anticoagulation therapy should be managed in the community with treatment aimed at standard targets and increased recall intervals.J Thromb Haemost2008;
6: 1645–1646.
11.
WittDMDelateTClarkNPet al.
Outcomes and predictors of very stable INR control during chronic anticoagulation therapy.Blood2009;
114: 952–956.
12.
GoldbergMCoeuret-PellicerMRibetCet al.
Epidemiological studies based on medical and administrative databases? A potential strength in France. Médecine Sci MS2012;
28: 430–434.
13.
SchneeweissSAvornJ.A review of uses of health care utilization databases for epidemiologic research on therapeutics.J Clin Epidemiol2005;
58: 323–337.
14.
RosendaalFRCannegieterSCvan der MeerFJet al.
A method to determine the optimal intensity of oral anticoagulant therapy.Thromb Haemost1993;
69: 236–239.
15.
HeranBSAllanGMGreenLet al.Effect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial. Trials2016;
17: 391.
16.
HawesEMVieraAJ.Anticoagulation: monitoring of patients receiving anticoagulation. FP Essent2014;
422: 24–30.
17.
TidemanPATirimaccoRSt JohnAet al.
How to manage warfarin therapy.Aust Prescr2015;
38: 44–48.
18.
CannegieterSCRosendaalFRWintzenARet al.
Optimal oral anticoagulant therapy in patients with mechanical heart valves.N Engl J Med1995;
333: 11–17.
19.
SekaggyaCNalwangaDVon BraunAet al.Challenges in achieving a target international normalized ratio for deep vein thrombosis among HIV-infected patients with tuberculosis: a case series. BMC Hematol2016;
16: 16.
20.
KurtogluMKoksoyCHasanEet al.
Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.J Vasc Surg2010;
52: 1262–1270.
21.
AzarAJDeckersJWRosendaalFRet al.
Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients.Thromb Haemost1994;
72: 347–351.
22.
SinghPKalitaJMisraUK.Quality of anticoagulation therapy in neurological patients in a tertiary care hospital in north India.Indian J Med Res2016;
143: 428–433.
23.
PalaretiGLealiNCoccheriSet al.
Study on complications of oral anticoagulant therapy (ISCOAT).Lancet1996;
348: 423–428.
24.
HorstkotteDPiperCWiemerM.Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis1998;
1: 19–24.
25.
SnyderCMHelmsBEHallDL.Evaluation of INR monitoring frequency and time in therapeutic range.J Pharm Technol2008;
24: 255–260.
26.
WittDMSadlerMAShanahanRLet al.
Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy.Chest2005;
127: 1515–1522.
27.
SamsaGPMatcharDB.Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis2000;
9: 283–292.
28.
LefebvrePColemanCIBookhartBKet al.
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.J Med Econ2014;
17: 52–64.
29.
van LeentMWStevanovićJJansmanFGet al.
Cost-Effectiveness of dabigatran compared to vitamin-k antagonists for the treatment of deep venous thrombosis in the Netherlands using real-world data.PLoS One2015;
10: e0135054.
30.
WittDMDelateTClarkNPet al.
Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users.J Thromb Haemost2010;
8: 744–749.
31.
AnsellJHollowellJPengoVet al.
The international study of anticoagulation management (ISAM).J Thromb Thrombolysis2007;
23: 83–91.
32.
NamDSadhuAHirshJet al.
The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?J Arthroplasty2015;
30: 315–319.
33.
HuttenBAPrinsMHRedekopWKet al.
Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists.Thromb Haemost1999;
82: 1260–1263.
34.
VeegerNJPiersma-WichersMTijssenJGet al.
Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.Br J Haematol2005;
128: 513–519.
